Header Logo

Connection

ROBERT ATMAR to Antibodies, Viral

Back to Details
This is a "connection" page, showing publications ROBERT ATMAR has written about Antibodies, Viral.
ROBERT ATMAR
Connection Strength
7.049
Antibodies, Viral
  1. Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine. J Infect Dis. 2025 Oct 15; 232(4):971-981.
    View in: PubMed
    Score: 0.590
  2. Correlation of Genogroup I, Genotype 1 (GI.1) Norovirus Neutralizing Antibody Levels With GI.1 Histo-Blood Group Antigen-Blocking Antibody Levels. J Infect Dis. 2024 Dec 16; 230(6):1376-1379.
    View in: PubMed
    Score: 0.557
  3. A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies. J Infect Dis. 2024 May 15; 229(5):1402-1407.
    View in: PubMed
    Score: 0.534
  4. Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med. 2022 03 17; 386(11):1046-1057.
    View in: PubMed
    Score: 0.456
  5. Comparison of Microneutralization and Histo-Blood Group Antigen-Blocking Assays for Functional Norovirus Antibody Detection. J Infect Dis. 2020 02 18; 221(5):739-743.
    View in: PubMed
    Score: 0.398
  6. Serological Responses to a Norovirus Nonstructural Fusion Protein after Vaccination and Infection. Clin Vaccine Immunol. 2016 02; 23(2):181-3.
    View in: PubMed
    Score: 0.298
  7. Serological Correlates of Protection against a GII.4 Norovirus. Clin Vaccine Immunol. 2015 Aug; 22(8):923-9.
    View in: PubMed
    Score: 0.287
  8. Mucosal and Cellular Immune Responses to Norwalk Virus. J Infect Dis. 2015 Aug 01; 212(3):397-405.
    View in: PubMed
    Score: 0.281
  9. Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clin Vaccine Immunol. 2015 Feb; 22(2):221-8.
    View in: PubMed
    Score: 0.279
  10. Serum hemagglutination inhibition activity correlates with protection from gastroenteritis in persons infected with Norwalk virus. Clin Vaccine Immunol. 2012 Feb; 19(2):284-7.
    View in: PubMed
    Score: 0.226
  11. Serological responses to experimental Norwalk virus infection measured using a quantitative duplex time-resolved fluorescence immunoassay. Clin Vaccine Immunol. 2011 Jul; 18(7):1187-90.
    View in: PubMed
    Score: 0.217
  12. The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distances. Vaccine. 2026 Mar 19; 76:128348.
    View in: PubMed
    Score: 0.151
  13. SARS-CoV-2 spike sequence-based distance as a marker of binding antibody response to COVID-19 vaccines. Vaccine. 2025 Oct 24; 65:127738.
    View in: PubMed
    Score: 0.147
  14. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial. Clin Infect Dis. 2025 02 05; 80(1):223-227.
    View in: PubMed
    Score: 0.141
  15. Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boost. Nat Commun. 2025 Jan 17; 16(1):759.
    View in: PubMed
    Score: 0.140
  16. Anti-neuraminidase and anti-hemagglutinin stalk responses to different influenza a(H7N9) vaccine regimens. Vaccine. 2025 02 15; 47:126689.
    View in: PubMed
    Score: 0.140
  17. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults. Clin Infect Dis. 2024 06 14; 78(6):1757-1768.
    View in: PubMed
    Score: 0.134
  18. Safety and immunogenicity of Multimeric-001 (M-001) followed by seasonal quadrivalent inactivated influenza vaccine in young adults - A randomized clinical trial. Vaccine. 2023 04 17; 41(16):2716-2722.
    View in: PubMed
    Score: 0.123
  19. Effect of recent seasonal influenza vaccination on serum antibody responses to candidate pandemic influenza A/H5N1 vaccines: A meta-analysis. Vaccine. 2019 09 03; 37(37):5535-5543.
    View in: PubMed
    Score: 0.095
  20. Human noroviruses: recent advances in a 50-year history. Curr Opin Infect Dis. 2018 10; 31(5):422-432.
    View in: PubMed
    Score: 0.090
  21. Human Monoclonal Antibodies That Neutralize Pandemic GII.4?Noroviruses. Gastroenterology. 2018 12; 155(6):1898-1907.
    View in: PubMed
    Score: 0.090
  22. Identification and Characterization of Single-Chain Antibodies that Specifically Bind GI Noroviruses. PLoS One. 2017; 12(1):e0170162.
    View in: PubMed
    Score: 0.080
  23. Rapid Responses to 2 Virus-Like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults: A Randomized Controlled Trial. J Infect Dis. 2016 Sep 15; 214(6):845-53.
    View in: PubMed
    Score: 0.077
  24. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-na?ve subjects. Vaccine. 2015 Sep 22; 33(39):5225-34.
    View in: PubMed
    Score: 0.072
  25. Comparison of trivalent cold-adapted recombinant (CR) influenza virus vaccine with monovalent CR vaccines in healthy unselected adults. J Infect Dis. 1995 Jul; 172(1):253-7.
    View in: PubMed
    Score: 0.072
  26. Mapping broadly reactive norovirus genogroup I and II monoclonal antibodies. Clin Vaccine Immunol. 2015 Feb; 22(2):168-77.
    View in: PubMed
    Score: 0.069
  27. Characterization of cross-reactive norovirus-specific monoclonal antibodies. Clin Vaccine Immunol. 2015 Feb; 22(2):160-7.
    View in: PubMed
    Score: 0.069
  28. Robust mucosal-homing antibody-secreting B cell responses induced by intramuscular administration of adjuvanted bivalent human norovirus-like particle vaccine. Vaccine. 2015 Jan 15; 33(4):568-76.
    View in: PubMed
    Score: 0.069
  29. Identification of human single-chain antibodies with broad reactivity for noroviruses. Protein Eng Des Sel. 2014 Oct; 27(10):339-49.
    View in: PubMed
    Score: 0.067
  30. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis. 2013 Mar 15; 207(6):974-81.
    View in: PubMed
    Score: 0.061
  31. Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus. Clin Vaccine Immunol. 2012 Dec; 19(12):1980-3.
    View in: PubMed
    Score: 0.060
  32. Norovirus vaccine against experimental human Norwalk Virus illness. N Engl J Med. 2011 Dec 08; 365(23):2178-87.
    View in: PubMed
    Score: 0.056
  33. Evaluation of age-related differences in the immunogenicity of a G9 H9N2 influenza vaccine. Vaccine. 2011 Oct 19; 29(45):8066-72.
    View in: PubMed
    Score: 0.055
  34. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine. 2010 Feb 25; 28(9):2076-9.
    View in: PubMed
    Score: 0.049
  35. Contrasting effects of type I interferon as a mucosal adjuvant for influenza vaccine in mice and humans. Vaccine. 2009 Aug 27; 27(39):5344-8.
    View in: PubMed
    Score: 0.048
  36. Increasing doses of an inactivated influenza A/H1N1 vaccine induce increasing levels of cross-reacting antibody to subsequent, antigenically different, variants. J Infect Dis. 2008 Oct 01; 198(7):1016-8.
    View in: PubMed
    Score: 0.045
  37. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine. 2007 Jul 20; 25(29):5367-73.
    View in: PubMed
    Score: 0.041
  38. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med. 2006 May 22; 166(10):1121-7.
    View in: PubMed
    Score: 0.038
  39. The vaccine platform used for COVID-19 primary immunization shapes the quality of the human B cell response to a vaccine boost. Sci Transl Med. 2026 Feb 25; 18(838):eaeb9837.
    View in: PubMed
    Score: 0.038
  40. The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults. Vaccine. 2026 Apr 02; 77:128358.
    View in: PubMed
    Score: 0.038
  41. Safety and immunogenicity of ascending doses of influenza A(H7N9) inactivated vaccine with or without MF59?. Vaccine. 2025 02 15; 47:126702.
    View in: PubMed
    Score: 0.035
  42. Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial. Clin Infect Dis. 2023 08 22; 77(4):560-564.
    View in: PubMed
    Score: 0.032
  43. A Multicenter, Controlled Human Infection Study of Influenza A(H1N1)pdm09 in Healthy Adults. J Infect Dis. 2023 08 11; 228(3):287-298.
    View in: PubMed
    Score: 0.032
  44. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine. 2003 Jul 28; 21(24):3479-82.
    View in: PubMed
    Score: 0.032
  45. Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. Cell Rep Med. 2022 07 19; 3(7):100679.
    View in: PubMed
    Score: 0.029
  46. Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. J Infect Dis. 2021 11 22; 224(10):1712-1719.
    View in: PubMed
    Score: 0.028
  47. Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. Vaccine. 2001 Sep 14; 19(32):4635-43.
    View in: PubMed
    Score: 0.028
  48. High-Resolution Mapping of Human Norovirus Antigens via Genomic Phage Display Library Selections and Deep Sequencing. J Virol. 2020 12 09; 95(1).
    View in: PubMed
    Score: 0.026
  49. An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. Hum Vaccin Immunother. 2020 12 01; 16(12):3138-3145.
    View in: PubMed
    Score: 0.025
  50. Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents. Vaccine. 2019 08 23; 37(36):5161-5170.
    View in: PubMed
    Score: 0.024
  51. Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. Vaccine. 2019 05 01; 37(19):2561-2568.
    View in: PubMed
    Score: 0.023
  52. Respiratory tract viral infections in inner-city asthmatic adults. Arch Intern Med. 1998 Dec 7-21; 158(22):2453-9.
    View in: PubMed
    Score: 0.023
  53. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. Vaccine. 2017 03 23; 35(13):1675-1682.
    View in: PubMed
    Score: 0.020
  54. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol. 1996 Sep; 3(5):507-10.
    View in: PubMed
    Score: 0.020
  55. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015 Jul 21; 314(3):237-46.
    View in: PubMed
    Score: 0.018
  56. Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. Vaccine. 2015 Jan 01; 33(1):163-73.
    View in: PubMed
    Score: 0.017
  57. Development and application of an enzyme immunoassay for coronavirus OC43 antibody in acute respiratory illness. J Clin Microbiol. 1994 Oct; 32(10):2372-6.
    View in: PubMed
    Score: 0.017
  58. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol. 1994 Oct; 32(10):2468-73.
    View in: PubMed
    Score: 0.017
  59. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults. J Infect Dis. 2014 Dec 01; 210(11):1763-71.
    View in: PubMed
    Score: 0.017
  60. Prenatal passive transfer of maternal immunity in Asian elephants (Elephas maximus). Vet Immunol Immunopathol. 2013 Jun 15; 153(3-4):308-11.
    View in: PubMed
    Score: 0.015
  61. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One. 2012; 7(12):e50830.
    View in: PubMed
    Score: 0.015
  62. Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes. J Infect Dis. 2012 Oct 01; 206(7):1069-77.
    View in: PubMed
    Score: 0.015
  63. Prior infections with seasonal influenza A/H1N1 virus reduced the illness severity and epidemic intensity of pandemic H1N1 influenza in healthy adults. Clin Infect Dis. 2012 Feb 01; 54(3):311-7.
    View in: PubMed
    Score: 0.014
  64. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route. Vaccine. 2010 Apr 09; 28(17):3025-9.
    View in: PubMed
    Score: 0.012
  65. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009 Aug 13; 27(37):5091-5.
    View in: PubMed
    Score: 0.012
  66. Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J Infect Dis. 2007 Mar 15; 195(6):826-32.
    View in: PubMed
    Score: 0.010
  67. Inactivated influenza vaccination for people with spinal cord injury. Arch Phys Med Rehabil. 2004 Nov; 85(11):1886-9.
    View in: PubMed
    Score: 0.009
  68. Ribavirin aerosol treatment of bronchiolitis associated with respiratory syncytial virus infection in infants. Pediatrics. 1983 Nov; 72(5):613-8.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.